Nasus Pharma Announces Transition of Chief Financial Officer
TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition. Oren Elmaliach, the Company’s Director of Finance, has been appointed Interim Chief Financial Officer.
Covered in this story
What has happened since
- TE Connectivity is up 7.6% since this was published, 47 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $TEL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on TE Connectivity →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.